可通过表观遗传药物向MECP2-依赖性癌症:表观遗传癌症治疗的新作用
Manish Neupane1, Mukesh Kumar2, Malela A Mwamufiya3
1MSD (United States) Rahway, NJ United States.
Molecular cancer therapeutics
|December 11, 2025
概括
甲基CpG结合蛋白2 (MECP2) 作为一种瘤基因. 针对MECP2的表观遗传疗法对MECP2过度表达的癌症有希望,揭示了一种新的药物机制.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 甲基CpG结合蛋白2 (MECP2) 基因在各种人类癌症中被放大,通过表观遗传机制作为瘤基因起作用.
- 了解MECP2的作用对于在瘤学中确定新的治疗策略至关重要.
研究的目的:
- 研究MECP2作为癌症治疗点.
- 为了确定MECP2的表观遗传功能是否适应向治疗.
主要方法:
- 利用lentiviral短发针RNA (shRNA) 来准三阴性乳腺癌 (TNBC) 的MECP2异种移植.
- 评估了DNA甲基化和基因素脱乙酶抑制剂对癌细胞生长和异种移植的疗效.
- 研究了MECP2-MAPK通路相互作用和耐药性机制.
主要成果:
- 过度表达MECP2的人类癌细胞系表现出对蛋白质的依赖,对表观遗传药物有有效的反应.
- 激活的MAPK通路组件,如RAS,对这些表观遗传疗法产生了耐药性.
- 鉴定出PAK3激酶是MECP2诱导的MAPK激活的关键调解者,也是潜在的治疗标.
结论:
- 过度表达MECP2的瘤可能受益于针对MECP2.2的表观遗传疗法.
- 表观遗传药物表现出一种新的作用机制,受MAPK通路激活的影响.
- 在MECP2驱动的癌症中,PAK3是潜在的治疗标.
更多相关视频
10:26Toxicological Assays for Testing Effects of an Epigenetic Drug on Development, Fecundity and Survivorship of Malaria Mosquitoes
Published on: January 16, 2015
8.8K
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.8K
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Epigenetic Regulation
3.7K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.7K
Epigenetic Regulation
33.4K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
33.4K
Abnormal Proliferation
5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K
